Tirzepatide is a dual gastric inhibitory peptide/glucagon-like peptide 1 
(GIP/GLP-1) receptor agonist formulated as a synthetic linear peptide, based on 
the native GIP sequence. It has a prolonged half-life of 5 days, which enables 
once-weekly dosing. Studies have hitherto demonstrated its superiority in 
achieving optimal glycaemic control and body weight management, as compared with 
various agents used in the treatment of type 2 diabetes mellitus (T2DM), 
including GLP-1 receptor agonists. Thus, it is expected to enrich our 
therapeutic armamentarium in T2DM. However, further experience, notably longer 
follow-up data and information on cardiovascular effects, is still needed.